These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31269413)

  • 21. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
    Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
    Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
    Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
    Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer.
    Kawaguchi M; Yanokura M; Banno K; Kobayashi Y; Kuwabara Y; Kobayashi M; Nomura H; Hirasawa A; Susumu N; Aoki D
    Int J Oncol; 2009 Jun; 34(6):1541-7. PubMed ID: 19424571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
    Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
    Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
    Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
    Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.
    Bozzao C; Varvara D; Piglionica M; Bagnulo R; Forte G; Patruno M; Russo S; Piscitelli D; Stella A; Resta N
    Int J Biol Markers; 2012 Dec; 27(4):e366-74. PubMed ID: 23125007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.
    Zannoni GF; Improta G; Pettinato A; Brunelli C; Troncone G; Scambia G; Fraggetta F
    J Clin Pathol; 2016 Dec; 69(12):1088-1092. PubMed ID: 27153872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
    Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
    Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study.
    Ghasemi D; Ameli F; Nili F; Edjtemaei R; Sheikhhasani S
    BMC Cancer; 2022 Dec; 22(1):1362. PubMed ID: 36581850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
    Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
    Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular analysis of sporadic colon cancer].
    Hurtado C; Wielandt AM; Zárate AJ; Kronberg U; Castro M; Yamagiwa K; Ito T; Eishi Y; Contreras L; López-Köstner F
    Rev Med Chil; 2015 Mar; 143(3):310-9. PubMed ID: 26005817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
    Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
    Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent PIK3CA mutation in normal endometrial gland drives spheroid formation and may be involved in stem cell propagation.
    Sato S; Nakayama K; Kanno K; Sultana R; Ishikawa M; Ishibashi T; Yamashita H; Kyo S
    Cancer Sci; 2023 Jun; 114(6):2335-2344. PubMed ID: 36843384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters.
    Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
    Jin C; Hacking S; Liang S; Nasim M
    Int J Surg Pathol; 2020 Feb; 28(1):31-37. PubMed ID: 31311367
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.